From another study that employed BiTE to target tumor-specific antigens, the intravenous administration of CD3xPDL1 BiTE could activate CD3 positive T cells (either CD4 positive or CD8 positive) and NKT cells that specifically killed PD-L1 positive tumor cells. This evidence concerns the gene CD274 and neoplasm.